SPARCNSESUN PHARMA ADV.RES.CO.LTD· PharmaceuticalsMediumNeutral
Announced Mon, 13 Jul · 17:37 IST

SPARC: CEO Anil Raghavan elevated to MD and CEO; Dr. Thennati retires

Management Changes View source PDF

SPARC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹259.55
prior close
₹259.35
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-2.5-2.0-1.9-2.9-3.2-9.3-12.1-13.4-17.1
Up moveDown movePending
AI summary

SPARC's Board has approved the appointment of current CEO Mr. Anil Raghavan as Managing Director and CEO effective August 11, 2026, subject to shareholder approval at the August 10, 2026 AGM. Separately, Dr. Rajamannar Thennati will retire from the Board on completion of his term at the same AGM. Mr. Raghavan is an internal appointee with prior consulting experience at Arthur Andersen, KPMG, and Quintiles.

Likely market impact

Internal promotion of CEO to MD and CEO ensures leadership continuity; routine director retirement is unlikely to materially affect the stock.